Stocktoria
Harmony Biosciences Holdings, Inc. HRMY
Harmony Biosciences Holdings, Inc. (HRMY) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $868.5M at a 18.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.515 |
| Retained earnings / assets | 0.127 |
| EBIT / assets | 0.164 |
| Equity / liabilities | 2.168 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | 5/9 | 7.17 | 12.9 | +21.5% |
| ANIP | ANI PHARMACEUTICALS INC | 6/9 | 3.26 | 24.5 | +43.8% |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | 4/9 | 0.82 | — | — |
| IONS | IONIS PHARMACEUTICALS INC | 3/9 | 1.12 | — | +33.8% |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | 6/9 | 1.76 | 18.9 | +23.6% |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | 3/9 | -1.18 | — | +432.1% |
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
FAQ
Is HRMY financially healthy?
Harmony Biosciences Holdings, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does HRMY pay a dividend?
No, Harmony Biosciences Holdings, Inc. does not currently pay a dividend.
How profitable is HRMY?
In FY2025, Harmony Biosciences Holdings, Inc. had a net margin of 18.3% and a return on equity of 18.2%.
Is HRMY overvalued or undervalued?
Harmony Biosciences Holdings, Inc. trades at about 14.7× trailing earnings — near its 10-year norm (10-year range 13.5×–61.8×, median 15.4×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for HRMY?
The average Wall-Street price target for Harmony Biosciences Holdings, Inc. is $44.36, about 11.6% above the recent price, from 11 analysts (consensus: buy).
Is HRMY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Harmony Biosciences Holdings, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 12.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.